StoneCo (NASDAQ:STNE) Bolsa

StoneCo

StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

FIVE

STNE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: SIG, WSM, HQY, STNE y FIVE.

5 acciones en el foco este miércoles: SIG, WSM, HQY, STNE y FIVE

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

GETY

SGMO

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: IHS, HQY, GETY, SGMO y STNE.

5 acciones en el foco este martes: IHS, HQY, GETY, SGMO y STNE

StoneCo Ltd

<a href="https://truthsocial.com/@realDonaldTrump/posts/114898069194751986" title="https://truthsocial.com/@realDonaldTrump/posts/114898069194751986">https://truthsocial.com/@realDonaldTrump/posts/114898069194751986</a>

Macro Economic Events

Politics

Global

Economics

General

ISHARES MSCI PHILIPPINES INVESTABLE MARKET INDEX FUND

EPHE

President Trump Posts On Truth Social "President Ferdinand Marcos, of the Philippines, is just leaving the White House, with all of his many Representatives. It was a beautiful visit, and we concluded our Trade Deal, whereby The Philippines is going OPEN MARKET with the United States, and ZERO Tariffs. The Philippines will pay a 19% Tariff."

Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework.
This internal review is part of Liminatus's continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments—including blockchain-based assets—that may enhance treasury efficiency and diversify non-operating capital reserves.
Liminatus emphasizes that this is an exploratory process only. As of today, the Company has not entered into any agreements regarding the acquisition, custody, or use of digital assets. Any potential future steps would be subject to approval by the Board of Directors and undertaken in full alignment with U.S. Securities and Exchange Commission (SEC) regulations and public company disclosure standards.

LIMN

Liminatus Pharma Initiates Strategic Review To Evaluate Potential Inclusion Of Regulated Digital Asset Strategies As Part Of Broader Treasury Management Framework

An all-in-one Supercharging station, dine-in restaurant, and drive-in movie theater<a href="https://www.benzinga.com/markets/large-cap/25/07/46505352/elon-musks-hitchhikers-galaxy-meets-buc-ees-drive-in-restaurant-nears-completion-will-tesla-accept-dogecoin"> years in the making</a> from Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has finally opened.
The location brings a unique menu of food options that Health and Human Services Secretary Robert F. Kennedy Jr. would approve of.
What Happened: After <a href="https://www.benzinga.com/general/restaurants/25/04/44939582/tesla-drive-in-movie-theater-diner-supercharger-location-could-be-close-to-opening">years of waiting,</a> Tesla fans can now visit the Tesla Diner Supercharging station that could be best described as Hitchhiker's Galaxy meets Buc-ee's meets EV charging.
The diner and drive-in movie theater is open 24 hours a day, seven days a week, and is not exclusive to Tesla owners. According to the company, the West Hollywood, California location <a href="https://www.tesla.com/support/tesla-diner">offers </a>"a classic American diner experience with a retro-futuristic twist."
Tesla owners can order directly from their vehicle using the Tesla Diner app. Other guests can choose to dine inside the two-story restaurant, with the rooftop Skypad providing views of the giant movie screens.
Tesla says its menu features a "wide variety of responsibly sourced and local products." Several vegetarian options are available.
Among the menu items that stand out are French fries cooked in beef tallow and sodas featuring real cane sugar. These items follow the "Make America Healthy Again" movement, inspired by Kennedy.
Restaurant company Steak ‘n Shake, which is owned by Biglari Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BH#NYSE">BH</a>), recently launched beef tallow for its cooking method for fries and other items and went viral. Kennedy <a href="https://www.benzinga.com/general/restaurants/25/03/44280041/rfk-jr-thanks-steak-n-shake-for-rfking-the-french-fries-restaurant-goes-all-in-on-make-america-healthy-again">approved of the change</a> and even visited a location.
Kennedy has not commented on the Tesla Diner yet, but perhaps in the future he'll make a trip to the location to support a restaurant that is attempting to popularize some of his "Make America Healthy Again" pushes.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Tesla Diner Menu: The Tesla Diner menu is available on the company's <a href="https://www.tesla.com/diner-webapp/menu/#5068f68d-cdd4-4ab2-8183-1835d9b76646">website </a>and shows products, prices and pictures to give people a better idea of what they can order. Here are the current food offerings:
<ul class="wp-block-list">
<li>Tesla Burger</li>
<li>Hot Dog</li>
<li>Diner Club Sandwich</li>
<li>Tuna Melt</li>
<li>Fried Chicken &amp; Waffles</li>
<li>Grilled Cheese</li>
<li>Egg Sandwich</li>
<li>Greek Yogurt Parfait</li>
<li>Breakfast Tacos</li>
<li>Biscuits &amp; Red Gravy</li>
<li>House Baked Cinnamon Roll</li>
<li>French Fries</li>
<li>Hash Brown Bites</li>
<li>Cup of Wagyu Beef Chili</li>
<li>Buttermilk Waffle</li>
<li>Market Salad</li>
<li>Epic Bacon</li>
<li>Slice of Apple Pie a la Mode</li>
<li>Slide of Pecan Pie a la Mode</li>
<li>Chocolate Chip Cookie</li>
<li>Kids Burger</li>
<li>Kids Chicken Tenders</li>
</ul>
The drink menu includes hot and cold coffee options like Nitro Cold Brew, Espresso and Cappuccino. Fountain drinks available in several flavors like cola, diet cola and lemon-lime are made with cane sugar.
Shopping Options: Inside the Tesla Diner are also several merchandise options from the company including apparel, candy and Tesla merchandise.
"Guests can purchase exclusive Tesla merchandise, including apparel, lifestyle items and candy, only available at Tesla Diner," the company says on their website.
Tesla said the merchandise selection is constantly changing with new product releases. Current items for sale in the shop include the Tesla Bot Action Figure, Hollywood Retro Diner T-Shirts, Tesla Diner Truck Hats and Tesla Supercharged Gummies, according to <a href="https://www.teslarati.com/tesla-supercharger-diner-opens-menu-prices-features/">Teslarati</a>. 
Payment Options: According to Tesla's website, the diner does not accept cash as a form of payment. The diner accepts all major credit cards and Apple Pay. Tesla owners who have their orders delivered to their vehicle will pay with whichever payment method is on file in their Tesla app.
This may be a disappointment for cryptocurrency investors. Musk previously promised that Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) would be accepted at the diner, but that is not currently a direct payment option.
"And, of course, you can pay in Doge," Musk previously&nbsp;<a href="https://twitter.com/elonmusk/status/1494840576264454145" target="_blank" rel="noreferrer noopener">said</a>.
Time will tell if Musk's promise of Dogecoin as a payment option comes true.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44419119/making-kennedy-proud-again-new-poll-shows-34-of-diners-more-likely-to-try-food-cooked-in-beef-tallow">Making Kennedy Proud Again? New Poll Shows 34% Of Diners More Likely To Try Food Cooked In Beef Tallow</a></li>
</ul>
Image: Shutterstock

Restaurants

$DOGE

TSLA

Tesla, Musk Jump Into Make America Healthy Again With Beef Tallow Fries At Diner

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are in the spotlight Tuesday ahead of earnings this week. Here&#8217;s a look at what you <a href="https://www.benzinga.com/insights/earnings/25/07/46548621/a-look-ahead-teslas-earnings-forecast">need to know.</a> 
What To Know: Tesla is due to report financial results for the second quarter after the market close on Wednesday. The company is expected to report earnings of 42 cents per share and revenue of $22.79 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
In the first quarter, Tesla <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">missed analyst estimates</a> on the top and bottom lines. Total revenue fell 9% year-over-year as automotive revenue dropped 20% due to a decline in deliveries, Model Y updates and lower average selling prices.
Tesla didn&#8217;t provide guidance last quarter, but noted that the company would &#8220;revisit&#8221; 2025 guidance when it reports second-quarter results. The automotive business isn&#8217;t likely to be the focus this quarter, according to Wedbush&#8217;s Dan Ives, who reiterated an Outperform rating and price target of $500 on Tuesday. 
Ives said in the new note that investors will be focused on the AI initiatives that Tesla is working on, including robotaxis and the company&#8217;s Optimus humanoid bots. 
Tesla CEO Elon Musk&nbsp;<a href="https://www.benzinga.com/25/05/45529030/elon-musk-confirms-tesla-robotaxi-launch-is-on-track-for-next-month-these-things-happen-slowly-but-then-all-at-once" target="_blank" rel="noreferrer noopener">said</a>&nbsp;in May that autonomous and robotics would "overwhelmingly dominate" Tesla's future financial success. Tesla officially&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/46045542/tesla-launches-robotaxi-in-austin-elon-musk-calls-it-a-culmination-of-a-decade-of-hard-work" target="_blank" rel="noreferrer noopener">launched</a>&nbsp;its robotaxis in Austin last month.
&#8220;It starts with autonomous then robotics,&#8221; Ives said on Tuesday. 
The Wedbush analyst recently <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46305934/musk-tells-tesla-analyst-dan-ives-to-shut-up-but-hes-not-backing-down-this-is-the-time-for-a-plan">called on Tesla's board</a> to establish 25% voting control for Musk, which he believes would create a path for a potential merger between Tesla and Musk's&nbsp;xAI. Ives noted that investors will be listening for any updates on a potential xAI investment on Tesla&#8217;s earnings call on Wednesday.
Other analysts are less optimistic heading into Wednesday&#8217;s print with Goldman Sachs cutting its target from $315 to $285 and Mizuho lowering its target from $390 to $375 earlier this month. Guggenheim also maintained a Sell rating at the beginning of the month with a price target of $175. 
TSLA Price Action: Tesla shares were up 1.07% at $332.01 at the time of publication on Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Tesla stock is trading above its 50-day moving average of $324.98, indicating a bullish short-term trend. The stock is also trading above the 200-day moving average of $318.48, suggesting overall strength in the longer-term trend. Despite gaining nearly 40% over the past three months, Tesla shares are still down about 18% year-to-date. 
Tesla&#8217;s P/E ratio of 187.71 indicates a high valuation relative to earnings, reflecting strong market expectations for future growth. With a market cap of $1.06 trillion, Tesla remains a dominant player in the electric vehicle sector, though much of its valuation is centered around the company&#8217;s AI ambitions. Ives said on Tuesday that Tesla&#8217;s autonomous initiatives are worth $1 trillion alone over the next few years. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46549038/teslas-battery-boom-faces-a-global-shockwave-thanks-to-trump">Tesla&#8217;s Battery Boom Faces A Global Shockwave—Thanks To Trump</a></li>
</ul>
Photo: courtesy of Tesla.

Movers

Tesla Stock Is Trending Tuesday: What's Going On?

ARK Invest, led by Cathie Wood, has made a major equity investment in BitMine Immersion Technologies Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>), <a href="https://www.benzinga.com/pressreleases/25/07/n46541601/ark-invest-acquires-182-million-of-bitmine-immersion-bmnr-common-shares-enabling-bitmine-to-furthe" target="_blank" rel="noreferrer noopener">acquiring nearly 4.8 million shares</a> valued at $182 million across multiple ARK funds.
BitMine confirmed that the net proceeds of $177 million from this transaction will be used exclusively to buy Ethereum (ETH), as the firm pursues its goal of acquiring 5% of the circulating ETH supply.
Thomas &#8220;Tom&#8221; Lee, Chairman of BitMine&#8217;s Board of Directors and Head of Research at Fundstrat, lauded Cathie Wood&#8217;s ARK Invest for taking a substantial stake in BitMine. 
Also Read:<a href="https://www.benzinga.com/markets/equities/25/07/46487931/bitmine-surges-14-after-hours-as-ethereum-holdings-top-1-billion-just-days-after-250-million-raise" target="_blank" rel="noreferrer noopener"> BitMine Surges 14% After Hours As Ethereum Holdings Top $1 Billion Just Days After $250 Million Raise</a>
He highlighted her reputation as an early backer of breakthrough investments such as Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Bitcoin (CRYPTO: BTC/USD). Wood recently anchored her support behind Circle&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) high-profile IPO under the ticker CRCL.
Other major names backing BitMine&#8217;s Ethereum strategy include Founders Fund, Pantera Capital, Galaxy Digital, Kraken, Digital Currency Group, and the pseudonymous MOZAYYX. Their collective support points to renewed institutional interest in Ethereum as the crypto market gears up for what some believe could be the next bull cycle.
The move also reflects what many are calling the &#8220;<a target="_blank" href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46535966/peter-thiel-effect-cathie-wood-pours-175-million-into-bitmine-immersion-stock-as-founders-fund-backing-ethereum-spike-fuels-buzz" rel="noreferrer noopener">Peter Thiel effect</a>,&#8221; referring to the wave of capital entering Ethereum-related projects following strong signals from influential tech investors.
BitMine&#8217;s decision to allocate its latest raise to Ethereum is a bold signal of confidence in the asset&#8217;s long-term trajectory. As competition among crypto-focused firms intensifies, strategic backing from high-profile investors like Wood could shape the future of digital asset accumulation.
Related ETFs include Grayscale Ethereum Trust (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#OTCQX">ETHE</a>) and Bitwise Crypto Industry Innovators ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITQ#NYSE">BITQ</a>).
Price Action: BMNR shares are trading higher by 4.08% to $41.19 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46547741/peter-thiel-and-cathie-wood-just-boarded-tom-lees-ether-rocket" target="_blank" rel="noreferrer noopener">Peter Thiel And Cathie Wood Just Boarded Tom Lee&#8217;s Ether Rocket</a></li>
</ul>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

BITQ

BMNR

CRCL

ETHE

Cathie Wood Joins Crypto Heavyweights In Backing BitMine's Ethereum Play

Shares of Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are trading lower Tuesday afternoon, caught in a broader downturn affecting the semiconductor industry. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/AMD/news">need to know</a>.
What To Know: The sector-wide pressure appears linked to <a href="https://www.benzinga.com/markets/tech/25/07/46534661/500-billion-stumble-softbank-openais-massive-ai-vision-faces-setbacks">reports</a> that a massive artificial intelligence infrastructure project is facing significant headwinds, raising concerns about the near-term demand for high-performance chips.
The venture in question, a $500 billion project named &#8220;Stargate&#8221; by SoftBank and OpenAI, is reportedly scaling back its ambitious goals. Announced six months ago with plans for a $100 billion immediate investment, the project has yet to secure a major data center deal. 
According to <a href="https://www.benzinga.com/markets/tech/25/07/46534661/500-billion-stumble-softbank-openais-massive-ai-vision-faces-setbacks">reports</a>, persistent disagreements between SoftBank and OpenAI over strategy and control have stalled progress, reducing near-term plans to a much smaller facility in Ohio.
The news has dampened investor enthusiasm for chip stocks because <a href="https://www.benzinga.com/markets/tech/25/06/45898547/openai-looks-to-raise-40-billion-from-global-investors-including-saudi-arabias-pif-indias-reliance-industries-to-accelerate-ai-models-and-stargate-report">mega-projects</a> like Stargate are expected to be a primary driver of future growth. A delay or reduction in scope of such a large-scale build-out could temper the explosive demand for AI accelerators that has propelled stocks like AMD. 
While OpenAI has secured capacity elsewhere, the struggles of its flagship joint venture are casting a shadow over the outlook for AI spending, prompting a cautious pullback.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings, AMD shows exceptional strength in several key areas. The company earns an outstanding Growth score of 97.12, signaling powerful forward-looking prospects. 
It also posts strong scores for Quality at 79.65 and Momentum at 74.16, suggesting a fundamentally sound business with positive recent market performance. However, these strengths come at a high price, as reflected by a very low Value score of just 11.68. This indicates that, while a high-quality growth name, the stock is considered expensive on a valuation basis.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMD shares are trading lower by 1.57% to $154.53 Tuesday afternoon. The stock has a 52-week high of $174.05 and a 52-week low of $76.48.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46538668/apples-online-store-is-now-live-in-saudi-arabia-flagship-stores-coming-by-2026">Apple&#8217;s Online Store Is Now Live In Saudi Arabia, Flagship Stores Coming By 2026</a>
<h2 class="wp-block-heading">How To Buy AMD Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Advanced Micro Devices&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

AMD Stock Is Sliding Tuesday: What's Driving The Action?

RFIL

Watching RF Industries; Hearing Zacks Under $10 Newsletter Picks Stock

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter">https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter</a>

FDA Announces: As Of June 27, Baxter Has Reported 79 Serious Injuries And Two Deaths Associated With Infusion Pump Issue

WIIM

LNZA

LanzaTech Global shares are trading higher after the company announced it received a grant by the UK government to proposal sustainable aviation fuel production.

Quest Diagnostics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) delivered a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46539510/quest-diagnostics-reports-second-quarter-2025-financial-results-raises-guidance-for-full-year-2025" rel="noreferrer noopener">robust second quarter in 2025</a>, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.
However, the diagnostic test provider flagged potential headwinds from ongoing tariffs and the significant financial impact if the Protecting Access to Medicare Act (PAMA) is not deferred, setting the stage for a watchful eye on legislative and trade developments.
For the second quarter of 2025, the company reported sales of $2.76 billion, a 15.2% increase year-over-year, exceeding the c<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">onsensus of $2.73 billion</a>. Adjusted earnings reached $2.62 per share, up 11.5%, also surpassing the consensus of $2.58.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46102684/could-personalized-medicine-be-your-portfolios-next-big-winner-find-out" rel="noreferrer noopener">Could Personalized Medicine Be Your Portfolio&#8217;s Next Big Winner? Find Out</a>
&#8220;Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full-year 2025 guidance,&#8221; said&nbsp;Jim Davis, chairman, CEO, and president.
Revenue per requisition decreased by 0.4%, requisition volume increased 16.3% and organic requisition volume improved by 2.1%. Adjusted Operating income increased 17.3% to $466 million, while the margin improved marginally from 16.6% to 16.9%.
During the earnings conference call, a Quest Diagnostics executive indicated that the company experienced some negative impact from tariffs in the second quarter and anticipates this will continue through the third and fourth quarters.
Furthermore, the executive reportedly stated that if the Protecting Access to Medicare Act (PAMA) is not deferred for another year, the financial impact to Quest Diagnostics would be approximately $100 million.
This suggests that Quest Diagnostics is facing a dual challenge: ongoing costs related to current tariffs and a significant potential financial hit if PAMA provisions are not postponed. The company&#8217;s future financial performance will likely be closely tied to developments on both of these fronts.
Outlook:&nbsp;Quest Diagnostics revised 2025 guidance for revenue from <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">$10.70 billion-$10.85 billion</a> to $10.80 billion-$10.92 billion versus the consensus of $10.79 billion.
The company expects adjusted earnings of $9.63-$9.83 compared to prior guidance of $9.55-$9.80 and the consensus of $9.70.
Reflecting the positive sentiment from the company&#8217;s strong results and raised outlook, investment firm William Blair provided its assessment, &#8220;Quest continues to showcase itself as a predictable revenue and earnings grower, and we remain confident in the updated 2025 guide and longer-term targets.&#8221;
Shares are trading at 16 times expected earnings over the next 12 months, slightly above the 10-year average of 15 times. Analyst Andrew F. Brackmann believes this higher valuation is justified due to the sector&#8217;s supportive economic environment, steady revenue and profit growth, and favorable market trends for reference labs. William Blair has reiterated its <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">Outperform</a> rating on the stock.
Price Action: DGX stock is trading higher by 6.19% to $176.75 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46546792/mscis-q2-success-fueled-by-record-etf-growth-diverse-client-expansion" target="_blank" rel="noreferrer noopener">MSCI&#8217;s Q2 Success Fueled By Record ETF Growth, Diverse Client Expansion</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Guidance

Health Care

Reiteration

Analyst Ratings

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

<a href="https://www.pdports.co.uk/news/brookfield-asset-management-agrees-to-sell-a-49-stake-in-pd-ports/" title="https://www.pdports.co.uk/news/brookfield-asset-management-agrees-to-sell-a-49-stake-in-pd-ports/">https://www.pdports.co.uk/news/brookfield-asset-management-agrees-to-sell-a-49-stake-in-pd-ports/</a>

Asset Sales

'Brookfield Asset Management Agrees To Sell A 49% Stake In PD Ports' - PD Ports

<h3>Gainers</h3>
<ul>
<li>Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) stock rose 44.4% to $2.96 during Tuesday's regular session. The company's market cap stands at $202.0 million. </li>
<li>Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) stock moved upwards by 31.81% to $13.74. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Kirkland's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) stock increased by 28.74% to $1.84. The company's market cap stands at $32.1 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) stock moved upwards by 26.66% to $1.33. The company's market cap stands at $4.2 million. </li>
<li>1-800-Flowers.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) stock increased by 25.77% to $6.49. The market value of their outstanding shares is at $327.9 million. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock moved upwards by 23.4% to $1.69. The company's market cap stands at $146.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) shares fell 45.0% to $1.38 during Tuesday's regular session. </li>
<li>Majestic Ideal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) stock declined by 25.18% to $2.17. The market value of their outstanding shares is at $59.4 million. </li>
<li>Happy City Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCHL#NASDAQ">HCHL</a>) stock declined by 11.34% to $4.46. The market value of their outstanding shares is at $96.0 million. </li>
<li>Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares declined by 10.87% to $10.96. The market value of their outstanding shares is at $152.1 million. </li>
<li>Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) stock declined by 10.4% to $15.0. The market value of their outstanding shares is at $9.1 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 9.86% to $0.63. The market value of their outstanding shares is at $26.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHGG

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FLWS

GDHG

HCHL

KIRK

LGCY

MJID

VLCN

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 54.8% to $1.41 during Tuesday's regular session. The company's market cap stands at $4.8 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares rose 51.65% to $468.44. The company's market cap stands at $8.8 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares increased by 37.06% to $4.32. The market value of their outstanding shares is at $75.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares moved upwards by 25.75% to $5.86. The market value of their outstanding shares is at $421.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 23.04% to $6.54. The market value of their outstanding shares is at $3.7 million. </li>
<li>IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) stock rose 18.58% to $188.5. The company's market cap stands at $27.5 billion. As per the press release, Q2 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock declined by 75.5% to $3.02 during Tuesday's regular session. The market value of their outstanding shares is at $950.0 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 28.44% to $2.19. The market value of their outstanding shares is at $113.2 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 26.93% to $2.05. The company's market cap stands at $16.9 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 20.9% to $1.45. The company's market cap stands at $7.3 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares declined by 17.67% to $42.4. The market value of their outstanding shares is at $2.2 billion. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 16.54% to $0.11. The company's market cap stands at $1.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

ATNF

BDMD

CELU

FTRE

MEDP

NNNN

PLRZ

REPL

TNFA

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares increased by 93.8% to $0.52 during Tuesday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) shares moved upwards by 64.34% to $7.03. The company's market cap stands at $3.6 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock increased by 41.11% to $0.07. The market value of their outstanding shares is at $1.6 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) stock rose 31.4% to $2.05. The company's market cap stands at $20.1 million. </li>
<li>Erayak Power Solution Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAYA#NASDAQ">RAYA</a>) shares rose 19.17% to $0.19. The market value of their outstanding shares is at $7.2 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock increased by 16.65% to $0.25. The company's market cap stands at $26.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares declined by 20.6% to $0.5 during Tuesday's regular session. The company's market cap stands at $4.7 million. </li>
<li>Knightscope (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>) shares fell 13.3% to $7.5. The market value of their outstanding shares is at $59.6 million. </li>
<li>BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) shares fell 13.13% to $19.4. The market value of their outstanding shares is at $778.2 million. </li>
<li>Toppoint Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#AMEX">TOPP</a>) shares decreased by 11.27% to $1.75. The company's market cap stands at $34.4 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock fell 10.53% to $0.78. The market value of their outstanding shares is at $10.9 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) stock decreased by 10.45% to $0.88. The company's market cap stands at $76.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIYA

BlackSky Technology Inc. Class A Common Stock

BKSY

DFLI

HTCO

HTOO

KSCP

RAYA

TOPP

WLGS

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) shares rose 23.3% to $2.54 during Tuesday's regular session. The company's market cap stands at $257.5 million. </li>
<li>Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) shares increased by 21.51% to $19.99. The market value of their outstanding shares is at $489.7 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock increased by 19.99% to $2.4. The company's market cap stands at $129.0 million. </li>
<li>Daqo New Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) stock rose 18.51% to $24.96. The company's market cap stands at $1.3 billion. </li>
<li>Foxx Development Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXX#NASDAQ">FOXX</a>) shares rose 11.85% to $6.04. The company's market cap stands at $36.6 million. </li>
<li>Mega Fortune Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRT#NASDAQ">MGRT</a>) shares moved upwards by 10.62% to $3.57. The company's market cap stands at $44.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares declined by 44.9% to $0.47 during Tuesday's regular session. The market value of their outstanding shares is at $47.6 million. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) shares declined by 32.12% to $0.53. The market value of their outstanding shares is at $25.9 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares decreased by 14.71% to $1.16. The company's market cap stands at $38.4 million. </li>
<li>Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) stock decreased by 13.4% to $212.38. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q2 earnings came out today. </li>
<li>Ouster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>) shares decreased by 11.19% to $26.04. The market value of their outstanding shares is at $1.5 billion. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) stock declined by 9.9% to $1.64. The market value of their outstanding shares is at $289.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHR

AIRE

CMBM

FOXX

LWLG

MGRT

Nuveen California Dividend Advantage Municipal Fund 2

OUST

PCLA

TDTH

12 Information Technology Stocks Moving In Tuesday's Intraday Session

The U.S. Food and Drug Administration appointed George F. Tidmarsh on Monday as director of the Center for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Drug Evaluation and Research (CDER)</a>.
Tidmarsh earned his M.D. and Ph.D. in cancer biology from Stanford University, where he completed residency training in pediatrics.
He completed <a href="https://www.fda.gov/news-events/press-announcements/stanford-faculty-member-george-tidmarsh-md-phd-named-director-center-drug-evaluation-and-research" target="_blank" rel="noreferrer noopener">two</a> subspecialty programs at Stanford, one in pediatric oncology and another in neonatology. He brings over 30 years of experience in biotechnology, clinical medicine and regulatory science, and has authored 143 scientific publications and patents. 
Tidmarsh is stepping in as the FDA faces major changes under Health and Human Services Secretary Robert F. Kennedy Jr.
Kennedy has pushed for <a href="https://www.benzinga.com/general/health-care/25/05/45326217/trumps-hhs-overhaul-faces-legal-blowback-from-states-over-deep-staffing-cuts-slashed-programs" target="_blank" rel="noreferrer noopener">large staff cuts at HHS</a> and has hired some people who share his <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">doubts about vaccines</a>.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46219622/trump-administrations-health-agency-overstepped-authority-reorganization-unlawful-court" target="_blank" rel="noreferrer noopener">Trump&#8217;s HHS Overhaul Faces Legal Blowback From States Over Deep Staffing Cuts, Slashed Health Programs</a>
Still, the pharmaceutical industry may feel some relief with Tidmarsh&#8217;s appointment. He has a strong background in drug development, having helped bring seven approved drugs to market. However, his past remarks suggest he might take a tougher stance on drug regulation.
Citing an opinion piece published in April, CNBC <a href="https://www.cnbc.com/2025/07/21/fda-george-tidmarsh-as-rfk-jr-top-drug-regulator.html" target="_blank" rel="noreferrer noopener">says</a> Tidmarsh criticized decisions made by Peter Marks, a top FDA official removed under Kennedy. Tidmarsh opposed the fast-tracking of Biogen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) controversial Alzheimer&#8217;s drug Aduhelm and disagreed with the decision to expand approval for Sarepta Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) muscular dystrophy drug Elevidys, which overruled FDA staff.
Tidmarsh&#8217;s appointment &#8220;brings in a generally well-respected, credible industry veteran, we believe helping fill a key regulatory void,&#8221; Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-07-21/fda-to-name-biotech-executivey-george-tidmarsh-as-rfk-jr-s-top-drug-regulator" rel="noreferrer noopener">wrote</a>, citing Brian Abrahams, an analyst at RBC Capital Markets.
While recent cuts at the agency have raised concerns about the FDA&#8217;s drug approval process, &#8220;we would expect Tidmarsh to be a pragmatic officer who will likely build upon current practice to ensure continuity and potentially be an advocate for the industry.&#8221;
The Bloomberg report added that one of the big challenges facing Tidmarsh is the FDA's accelerated drug approval process. This faster track for getting drugs approved has become more common in recent years. While supporters say it helps patients with serious illnesses get treatments faster, critics argue it allows some unproven drugs to stay on the market for too long.
Tidmarsh is also expected to play a major role in rethinking how the agency regulates prescription drug advertising. Kennedy Jr. has been outspoken against drug ads aimed at consumers, and agency official Marty Makary said the current rules are under review.
Last year, at a Stanford panel on censorship and scientific speech, Tidmarsh criticized the FDA for being inconsistent in regulating drugs.
He pointed out the agency's strict rules on how drugmakers can talk about off-label uses and questioned some vaccine ads shown during the COVID-19 pandemic.
Read Next:
<a href="https://www.benzinga.com/markets/large-cap/25/07/46525621/roper-tech-lifts-2025-outlook-as-ai-acquisitions-fuel-double-digit-growth" target="_blank" rel="noreferrer noopener">Roper Tech Lifts 2025 Outlook As AI, Acquisitions Fuel Double-Digit Growth</a>
Photo: jittawit21 via Shutterstock

Biotech

Government

Management

BIIB

SRPT

FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division

<a href="https://www.sprucepointcap.com/research/an-overheated-hvac-growth-story" title="https://www.sprucepointcap.com/research/an-overheated-hvac-growth-story">https://www.sprucepointcap.com/research/an-overheated-hvac-growth-story</a>

Short Sellers

Watching Limbach Holdings; Spruce Point Capital Issues Report On The Co Stating They Are Short

DDC Enterprise shares are trading higher. The company announced a $500 million mixed shelf offering.

<ul>
<li>Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial</li>
<li>Data will include patients from the dose escalation and at multiple expansion doses</li>
<li>U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025</li>
</ul>
JIANGSU, China and SOUTH SAN FRANCISCO, Calif., July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, today announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC), taking place September 6-9, 2025 in Barcelona, Spain. The presentation will cover efficacy and safety results in&nbsp;SCLC from the Phase 1 trial Hengrui is conducting in China for IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). DLL3 is&nbsp;upregulated across multiple solid tumor types where significant unmet need remains, including SCLC, neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC) and melanoma.&nbsp;

IDYA

IDEAYA Biosciences To Present Clinical Efficacy And Safety Data From Over 70 Small-Cell Lung Cancer Patients In Hengrui's Ongoing, Multi-Site, Open Label Phase 1 Trial, At IASLC 2025 World Conference

Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-23. Here's what investors need to know before the announcement.
Analysts estimate that Oceaneering International will report an earnings per share (EPS) of $0.41. 
Anticipation surrounds Oceaneering International's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 3.76% increase in the share price on the subsequent day.
Here's a look at Oceaneering International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.31</td>
<td>0.41</td>
<td>0.44</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.43</td>
<td>0.37</td>
<td>0.36</td>
<td>0.28</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>14.000000000000002%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753203771_0.png" alt="eps graph" />
<h3>Market Performance of Oceaneering International's Stock</h3>
Shares of Oceaneering International were trading at $20.77 as of July 21. Over the last 52-week period, shares are down 16.46%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Oceaneering International</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Oceaneering International.
Analysts have given Oceaneering International a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $21.0, indicating a potential 1.11% upside.
<h3>Comparing Ratings with Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Liberty Energy, Tidewater and Flowco Holdings, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Liberty Energy, with an average 1-year price target of $14.75, suggesting a potential 28.98% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Tidewater, with an average 1-year price target of $70.0, suggesting a potential 237.02% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Flowco Holdings, with an average 1-year price target of $32.5, suggesting a potential 56.48% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary provides a snapshot of key metrics for Liberty Energy, Tidewater and Flowco Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oceaneering International</td>
<td>Neutral</td>
<td>12.59%</td>
<td>$135.01M</td>
<td>6.77%</td>
</tr>
<tr>
<td>Liberty Energy</td>
<td>Neutral</td>
<td>-8.91%</td>
<td>$88.10M</td>
<td>1.02%</td>
</tr>
<tr>
<td>Tidewater</td>
<td>Outperform</td>
<td>3.82%</td>
<td>$101.60M</td>
<td>3.83%</td>
</tr>
<tr>
<td>Flowco Holdings</td>
<td>Outperform</td>
<td>188.33%</td>
<td>$65.81M</td>
<td>2.63%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Oceaneering International ranks in the middle among its peers for Consensus rating. It ranks at the bottom for Revenue Growth and Gross Profit, but at the top for Return on Equity.
<h3>All You Need to Know About Oceaneering International</h3>
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
<h3>A Deep Dive into Oceaneering International's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Oceaneering International's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 12.59%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Oceaneering International's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.47%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Oceaneering International's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.77%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Oceaneering International's ROA excels beyond industry benchmarks, reaching 2.18%. This signifies efficient management of assets and strong financial health.
Debt Management: Oceaneering International's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.08, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/OII/earnings">To track all earnings releases for Oceaneering International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Oceaneering International's Earnings Outlook

Press Releases

StoneCo Announces Additional Board Change

StoneCo Ltd. to Announce Third Quarter 2024 Financial Results on November 12th, 2024

StoneCo Reports Third Quarter 2024 Results

StoneCo. Announces New Share Repurchase Program of up to R$ 2 billion

StoneCo Ltd. to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 18th, 2025

StoneCo Reports Fourth Quarter and Fiscal Year 2024 Results

StoneCo Ltd. to Announce First Quarter 2025 Financial Results on May 08th, 2025

StoneCo Reports First Quarter 2025 Results

StoneCo Ltd. to Announce Second Quarter 2025 Financial Results on August 07th, 2025

Comments

StoneCo

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL